Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

Glioblastoma is the most common primary central nervous system malignancy and has a poor prognosis. Standard first-line treatment, which includes surgery followed by adjuvant radio-chemotherapy, produces only modest benefits to survival1,2. Here, to explore the feasibility, safety and immunobiologic...

Descrizione completa

Dettagli Bibliografici
Autori principali: Schalper, K.A. (Kurt A.), Rodriguez-Ruiz, M.E. (María Esperanza), Diez-Valle, R. (Ricardo), López-Janeiro, Á. (Álvaro), Porciuncula, A. (Angelo), Idoate, M.A. (Miguel Ángel), Inoges, S. (Susana), Andrea, C.E. (Carlos Eduardo) de, Lopez-Diaz-de-Cerio, A. (Ascensión), Tejada-Solis, S. (Sonia), Berraondo, P. (Pedro), Villarroel-Espindola, F. (Franz), Choi, J. (Jungmin), Gurpide, A. (Alfonso), Giraldez, M. (Miriam), Goicoechea, I. (Iosune), Gallego-Perez-Larraya, J. (Jaime), Fernandez-Sanmamed, M. (Miguel), Perez-Gracia, J.L. (Jose Luis), Melero, I. (Ignacio)
Natura: info:eu-repo/semantics/article
Lingua:eng
Pubblicazione: Nature Publishing Group 2024
Soggetti:
Materias Investigacion::Ciencias de la Salud::Oncología
Glioblastoma
Neoadjuvant nivolumab
Accesso online:https://hdl.handle.net/10171/68722

Accesso online

https://hdl.handle.net/10171/68722

Documenti analoghi